These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1254 related items for PubMed ID: 24338939

  • 1. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.
    Cancer; 2014 Mar 15; 120(6):855-63. PubMed ID: 24338939
    [Abstract] [Full Text] [Related]

  • 2. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, Baxter-Lowe LA, Luisi P, Militano O, Kletzel M, Cairo MS.
    Biol Blood Marrow Transplant; 2016 Apr 15; 22(4):698-704. PubMed ID: 26785332
    [Abstract] [Full Text] [Related]

  • 3. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun 15; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.
    J Clin Oncol; 2013 Oct 01; 31(28):3549-56. PubMed ID: 23980086
    [Abstract] [Full Text] [Related]

  • 5. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H, Ozdemir E, Uz B, Buyukasik Y, Turgut M, Serefhanoglu S, Aksu S, Sayinalp N, Haznedaroglu IC, Tekin F, Karacan Y, Unal S, Eliacik E, Isik A, Ozcebe OI.
    Transfus Apher Sci; 2013 Dec 01; 49(3):590-9. PubMed ID: 23981652
    [Abstract] [Full Text] [Related]

  • 6. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
    Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N.
    Cancer; 2005 Nov 01; 104(9):1931-8. PubMed ID: 16178004
    [Abstract] [Full Text] [Related]

  • 7. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M.
    Cancer; 2015 Apr 01; 121(7):1048-55. PubMed ID: 25424330
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
    Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Büchner T.
    J Clin Oncol; 2014 Feb 01; 32(4):288-96. PubMed ID: 24366930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.
    Bone Marrow Transplant; 2000 May 01; 25(10):1021-8. PubMed ID: 10828860
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
    Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S.
    Biol Blood Marrow Transplant; 2012 Dec 01; 18(12):1845-50. PubMed ID: 22766221
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.
    J Cancer Res Clin Oncol; 2016 Jan 01; 142(1):317-24. PubMed ID: 26424692
    [Abstract] [Full Text] [Related]

  • 20. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.
    Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringdén O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR.
    Biol Blood Marrow Transplant; 2014 Feb 01; 20(2):202-8. PubMed ID: 24184335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.